HK:6660 Stock Latest News
Company AnnouncementsAIM Vaccine Delays EGM to Revise Domestic Unlisted Share Issuance Plan2M ago6660
Company AnnouncementsAIM Vaccine Seeks Approval for High-Potency Human Diploid Cell Rabies Shot2M ago6660
Company AnnouncementsAIM Vaccine Interim Revenue Slides as Losses Narrow Slightly2M ago6660
Company AnnouncementsAIM Vaccine Revises Domestic Share Issuance and Secures Key Subscriptions2M ago6660
Company AnnouncementsAIM Vaccine Seeks Shareholder Nod for Private Domestic Share Issue and Dual Mainland Listings2M ago6660
Company AnnouncementsAIM Vaccine Sets August Board Meeting to Approve Interim Results and Consider Dividend2M ago6660Company AnnouncementsAIM Vaccine Advances Serum-Free Rabies Shot Toward China Market Approval3M ago6660
Company AnnouncementsAIM Vaccine Wins Strong Shareholder Backing for 2025 Results and Board Changes4M ago6660
- Company AnnouncementsAIM Vaccine Details Board Structure and Governance Committees4M ago6660
- Company AnnouncementsAIM Vaccine Wins Shareholder Backing for Mainland Share Issue and Dual-Market Push4M ago6660
Company AnnouncementsAIM Vaccine Books Impairments as It Pauses mRNA Rabies Projects and Delays PCV13 Launch4M ago6660
Company AnnouncementsAIM Vaccine Seeks Shareholder Nod for RMB Share Issue and Dual Listing on NEEQ and Beijing Bourse5M ago6660
Company AnnouncementsAIM Vaccine Reshapes Board with New Director Nominations After Resignation5M ago6660Company AnnouncementsAIM Vaccine Sets 2025 AGM to Approve Results, Board Changes and Capital Mandates5M ago6660
Company AnnouncementsAIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue Decline7M ago6660
- Company AnnouncementsAIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance7M ago6660
- Company AnnouncementsAIM Vaccine Sets March 30 Board Meeting to Approve 2025 Results and Consider Dividend7M ago6660
Company AnnouncementsAIM Vaccine Clears Key Regulatory Hurdle for World’s First Serum-Free Rabies Shot8M ago6660- Company AnnouncementsAIM Vaccine Wins Approval to Start Trials of 20-Valent Pneumococcal Shot9M ago6660
Company AnnouncementsAIM Vaccine Advances High-Potency Human Diploid Rabies Shot After Completing Phase III On-Site Work9M ago6660Company AnnouncementsAIM Vaccine Reshuffles Company Secretary and Authorised Representative Roles10M ago6660
Company AnnouncementsAIM Vaccine Reports Interim Results with Decreased Revenue and Improved Loss Management1y ago6660